Dishman Carbogen Amcis Performance
- Today's Low
- ₹197
- Today's High
- ₹203
- 52 Week Low
- ₹129
- 52 Week High
- ₹322
- Open Price₹201
- Previous Close₹201
- Volume205,727
- 50 DMA₹184.07
- 100 DMA₹193.58
- 200 DMA₹210.19
Dishman Carbogen Amcis Chart
Investment Returns
- Over 1 Month + 16.97%
- Over 3 Month + 6.92%
- Over 6 Month -19.05%
- Over 1 Year -27.29%
Smart Investing Starts Here Start SIP with Dishman Carbogen Amcis for Steady Growth!
Dishman Carbogen Amcis Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 31.8
- PEG Ratio
- 0
- Market Cap Cr
- 3,099
- P/B Ratio
- 0.5
- Average True Range
- 11.43
- EPS
- 6.32
- Dividend Yield
- 0
- MACD Signal
- 6.93
- RSI
- 57.18
- MFI
- 83.85
Latest Stock News Updates
Conference Call with Dishman Carbogen Amcis Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
- Trendlyne
- 3 months 3 weeks ago
Pharmaceuticals company Dishman Carbogen Amcis announced Q3FY26 results Revenue: Rs 719.8 crore against Rs 682.34 crore during Q3FY25, change 5%. PBT: Rs -10.44 crore against Rs 27.05 crore during Q3FY25. PAT: Rs -12.97 crore against Rs 4.63 crore during Q3FY25. EPS: Rs -0.83 for Q3FY26. Result PDF
- Trendlyne
- 3 months 3 weeks ago
Pharmaceuticals company Dishman Carbogen Amcis announced Q2FY25 results Net Revenue at Rs 7,890.4 million in Q2FY25 up by 34.5% YoY mainly due to increase in commercial sales in the CRAMS segment in Switzerland and India. Carbogen Amcis AG – CRAMS revenue increased by 51.7% YoY in Q2FY25 primarily due to higher commercial sales and also rollover of certain shipment which got pushed to Q2 from Q1FY25. Carbogen Amcis BV– Cholesterol and Vitamin D analogues revenue decreased by 35.7% YoY in Q2FY25 primarily due to lower sales of Cholesterol SF on account of lower margin realizations. DCAL India – NCE APIs and Intermediates revenue increased by 36.9% YoY in Q2FY25 primarily due to increase in commercial sales from Bavla site. DCAL India – Quats & Generics revenue decreased by 20.8% YoY in Q2FY25 primarily due to slowdown in the agrochemical sector. EBITDA Margin at 18.8% in Q2FY25 compared to 10.8% in Q2FY24 due to: Increase in operating margins in CARBOGEN AMCIS – CRAMS segment from 12.2% to 19.7% due to higher volume of commercial sales. Increase in operating margins at Carbogen Amcis BV from 10.1% to 14.7% due to higher sales of vitamin D analogues with higher margins. Increase in operating margins at DCAL India - NCE APIs & Intermediates to 13.9% compared to negative margins in Q2FY24 due to increase in operations in Bavla site. Net Debt excluding lease liabilities was CHF 173 million as on September 30, 2024. Capital expenditure for H1FY25 was approximately USD 15.9 million. Result PDF
- Trendlyne
- 1 year 6 months ago
Dishman Carbogen Amcis Financials
Dishman Carbogen Amcis Technicals
EMA & SMA
- Bearish Moving Average 5
- Bullish Moving Average 11
- 20 Day
- ₹190.23
- 50 Day
- ₹184.07
- 100 Day
- ₹193.58
- 200 Day
- ₹210.19
Resistance and Support
- R3 207.00
- R2 204.96
- R1 201.32
- S1 195.64
- S2 193.60
- S3 189.96
Dishman Carbogen Amcis Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-05-19 | Audited Results | |
| 2026-03-18 | To consider Fund Raising | |
| 2026-02-03 | Quarterly Results | |
| 2025-12-27 | To consider Fund Raising | |
| 2025-11-04 | Quarterly Results |
About Dishman Carbogen Amcis
- NSE Symbol
- DCAL
- BSE Symbol
- 540701
- Managing Director
- Mr. Arpit J Vyas
- ISIN
- INE385W01011
Similar Stocks to Dishman Carbogen Amcis
Popular Stocks
Dishman Carbogen Amcis FAQs
Dishman Carbogen Amcis share price is ₹197 As on 27 May, 2026 | 21:35
The Market Cap of Dishman Carbogen Amcis is ₹3099.4 Cr As on 27 May, 2026 | 21:35
The P/E ratio of Dishman Carbogen Amcis is 31.8 As on 27 May, 2026 | 21:35
The PB ratio of Dishman Carbogen Amcis is 0.5 As on 27 May, 2026 | 21:35
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.